Diligence memo · auto-generated · as of July 2, 2026
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Eupraxia Pharmaceuticals Inc. operates in Biotechnology, based in VICTORIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Eupraxia Pharmaceuticals Inc. has raised $2.4M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.9M on 2024-10-31.
Most recent recorded round closed around 2024-10-31.
Valuation (modeled)modeled
Provath models Eupraxia Pharmaceuticals Inc. at approximately $7.6M (range $1.4M–$19M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 71 months.
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 14.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 30% of Biotechnology peers (4293 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.